Device and method for preparing near-infrared two-zone developer
By designing a device containing a fluorescent substance container and a serum albumin mixing tank, the problem of long preparation time and contamination of NIR-II fluorescent developer in a sterile environment is solved, and the efficient preparation of developer in a sealed system is achieved, which enhances the Fluorescence intensity.
Patent Information
- Application Number
- CN202310942724.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-05-26
- Filing Date
- 2023-07-28
- Publication Date
- 2024-11-26
AI Technical Summary
The existing near-infrared second zone (NIR-II) fluorescent developer needs to be freshly prepared in a sterile environment before use, resulting in increased time-consuming pre-work and susceptible to contamination, affecting the development effect.
A device was designed, including a fluorescent substance container, a serum albumin mixing tank, a tube body and a flow control valve. By vertically setting and adjusting the mixing flow rate of the fluorescent substance and serum albumin, NIR-II developer is formed, avoiding contamination and Simplified the preparation process.
Preparing NIR-II developer in a sealed system reduces the risk of contamination, simplifies the operation process, and improves the purity and quality of the developer, significantly enhancing the fluorescence intensity in the wavelength range of 900-2000nm.
Smart Images

Figure CN119015916A_ABST
Abstract
Description
Technical Field
[0001] The present disclosure relates to the field of preparing near-infrared fluorescent developers, and more particularly, to an apparatus and method for preparing near-infrared second-zone fluorescent developers. Background Art
[0002] Contrast agents that can emit near-infrared-I (NIR-I) fluorescence have been widely used in the fields of biosensing and medical detection. However, the development effect of NIR-I contrast agents is often interfered by tissue autofluorescence and photon scattering, which in turn affects the image quality and tissue penetration depth.
[0003] Recently, it has been reported that near-infrared II (NIR-II) fluorescence has a longer wavelength than NIR-I fluorescence, so NIR-II fluorescent imaging agents can overcome the defects of existing NIR-I fluorescent imaging agents. Specifically, NIR-II imaging agents can penetrate deep tissues and have micron-level spatial resolution and high signal-to-background ratio. Therefore, NIR-II imaging agents are regarded as the most promising imaging agents in the field of in vivo fluorescence imaging technology.
[0004] Despite this, these NIR-II contrast agents still face the same problems as traditional contrast agents; that is, they need to be freshly prepared before use to achieve better contrast effects. Contrast agents used in clinical practice must be prepared in a sterile environment to avoid contamination, which greatly increases the time spent on preparatory work.
[0005] In view of this, there is an urgent need in the art for a novel device to prepare NIR-II developer more efficiently. Summary of the invention
[0006] The invention summary is intended to provide a simplified summary of the present disclosure so that readers can have a basic understanding of the present disclosure. This invention summary is not a complete overview of the present disclosure, and it is not intended to point out the important / critical elements of the embodiments of the present invention or to define the scope of the present invention.
[0007] The first aspect of the present disclosure is about a device for preparing a NIR-II developer from a fluorescent substance and serum albumin. According to certain embodiments of the present disclosure, the device includes a first container for accommodating a fluorescent substance; a mixing tank for receiving serum albumin; a first tube connected to the first container and the mixing tank; and a first flow regulating valve, which is operably coupled to the first tube to control the flow rate of the fluorescent substance flowing out of the first container. In these embodiments, the first container is vertically arranged above the mixing tank, so that the fluorescent substance can flow out of the first container and enter the mixing tank through the first tube, and then mix with the serum albumin therein to produce a NIR-II developer. When irradiated with light with an excitation wavelength of 500-830nm, the NIR-II developer prepared by the aforementioned device will significantly enhance the emission of NIR-II fluorescence with a wavelength range of 900-2,000nm.
[0008] According to certain embodiments of the present disclosure, the device further comprises a mixing element disposed in the mixing tank. Optionally or alternatively, the device further comprises a first and a second pressure regulating valve, respectively coupled to the first container and the mixing tank, for respectively controlling the pressure in the first container and the mixing tank.
[0009] According to an alternative embodiment of the present disclosure, the device further comprises a second container for accommodating serum albumin; a second tube connected to the second container and the mixing tank; and a second flow regulating valve, which is operably coupled to the second tube, for controlling the flow rate of serum albumin flowing out of the second container. In these embodiments, the second container is vertically arranged above the mixing tank, so that serum albumin can flow out of the second container and enter the mixing tank through the second tube. In certain preferred embodiments, the device further comprises a third pressure regulating valve, which is coupled to the second container, for controlling the pressure in the second container.
[0010] According to certain embodiments of the present disclosure, the fluorescent substance is a cyanine dye or a fluorescent nanoparticle. In certain preferred embodiments, the fluorescent substance is a cyanine dye. In a specific embodiment, the cyanine dye is the clinically approved near-infrared dye indocyanine green (ICG). According to alternative embodiments of the present disclosure, the fluorescent substance is a fluorescent nanoparticle. Exemplary fluorescent nanoparticles are fluorescent gold nanoclusters or silver sulfide quantum dots.
[0011] According to certain embodiments, the serum albumin is human serum albumin (HSA) or bovine serum albumin (BSA).
[0012] A second aspect of the present disclosure is a method for preparing a NIR-II developer using the apparatus described in one embodiment of the present disclosure. According to certain embodiments of the present disclosure, the method comprises the following steps:
[0013] (a) adding serum albumin to a mixing tank;
[0014] (b) allowing the fluorescent substance to flow out of the first container, enter the mixing tank through the first tube, and mix with the serum albumin in the mixing tank;
[0015] (c) adjusting the first flow regulating valve to control the flow rate of the fluorescent substance flowing out of the first container; and
[0016] (d) mixing the contents in the mixing tank of step (c) at a speed of 120-1,200 revolutions per minute to prepare a NIR-II developer.
[0017] According to certain embodiments of the present disclosure, the molar concentration ratio of the fluorescent substance to the serum albumin in the NIR-II developer is 1:1 to 1:500. Preferably, the molar concentration ratio of the fluorescent substance to the serum albumin in the NIR-II developer is 1:1 to 1:256. In one specific embodiment, the molar concentration ratio of the fluorescent substance to the serum albumin in the NIR-II developer is 1:2.
[0018] In certain embodiments, the fluorescent substance is cyanine dye, fluorescent gold nanoclusters or silver sulfide quantum dots, and the serum albumin is HSA or BSA.
[0019] A third aspect of the present disclosure is a method for preparing a NIR-II developer using the apparatus described in another embodiment of the present disclosure. According to certain embodiments of the present disclosure, the method includes adjusting the first and second flow regulating valves to control the flow rates of the fluorescent substance and serum albumin flowing out of the first and second containers and into the mixing tank, thereby preparing the NIR-II developer.
[0020] According to some preferred embodiments of the present disclosure, the molar concentration ratio of the fluorescent substance to the serum albumin in the NIR-II developer is 1:1 to 1:500. In some preferred embodiments, the molar concentration ratio of the fluorescent substance to the serum albumin in the NIR-II developer is 1:1 to 1:256. According to one specific embodiment, the molar concentration ratio of the fluorescent substance to the serum albumin in the NIR-II developer is 1:2.
[0021] According to an exemplary embodiment of the present disclosure, the fluorescent substance is cyanine dye, fluorescent gold nanoclusters or silver sulfide quantum dots, and the serum albumin is HSA or BSA.
[0022] After referring to the following embodiments, a person having ordinary knowledge in the technical field to which the present invention belongs can easily understand the basic spirit and other invention purposes of the present invention, as well as the technical means and implementation modes adopted by the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] In order to make the above and other objects, features, advantages and implementation modes of the present invention more obvious and understandable, the accompanying drawings are described as follows.
[0024] Figure 1 is a schematic diagram of a device 100 according to an embodiment of the present disclosure; and
[0025] Figure 2 is a schematic diagram of a device 200 according to another embodiment of the present disclosure.
[0026] According to the usual working method, the various features and components in the figure are not drawn to scale, and the drawing method is to present the specific features and components related to the present invention in the best way. In addition, the same or similar element symbols are used to refer to similar elements / components between different figures.
[0027] Description of Reference Numerals
[0028] 100, 200: Installation
[0029] 110, 210: First container
[0030] 120, 220: Mixing tank
[0031] 130, 230: First tube body
[0032] 140, 240: First flow regulating valve
[0033] 250: Second container
[0034] 260: Second tube body
[0035] 270: Second flow regulating valve DETAILED DESCRIPTION
[0036] In order to make the description of the present disclosure more detailed and complete, the following is an illustrative description of the implementation and specific embodiments of the present invention; however, this is not the only form of implementing or using the specific embodiments of the present invention. The implementation covers the features of multiple specific embodiments and the method steps and sequences used to construct and operate these specific embodiments. However, other specific embodiments can also be used to achieve the same or equivalent functions and step sequences.
[0037] Unless otherwise defined in this specification, the scientific and technical terms used herein have the same meanings as those understood and used by persons of ordinary skill in the technical field to which the present invention belongs. Furthermore, singular nouns used in this specification include plural forms of the nouns, and plural nouns used also include singular forms of the nouns, unless otherwise defined in this specification. Specifically, in this specification and claims, the singular forms "a" and "an" include plural reference values, unless otherwise indicated by the context. In addition, in this specification and claims, the expressions "at least one" and "one or more" have the same meaning, and both represent one, two, three or more.
[0038] The present disclosure aims to provide an apparatus and method for preparing NIR-II developer. Compared with the existing apparatus and process which must be operated in a sterile environment, the apparatus of the present disclosure is simple and easy to operate, wherein the NIR-II developer is prepared in a sealed system, avoiding the possibility of contamination and not adversely affecting the purity and / or quality of the developer.
[0039] Device for preparing NIR-II developer
[0040] The first aspect of the present disclosure is a device for preparing a NIR-II developer from a fluorescent substance and serum albumin. According to certain embodiments of the present disclosure, when irradiated with light having an excitation wavelength of 500-830 nanometers, the developer of the present disclosure will enhance the emission of NIR-II fluorescence with a wavelength range of 900-2,000 nanometers.
[0041] Figure 1 1 is a schematic diagram of a device 100 according to an embodiment of the present disclosure. As shown in the figure, the device 100 structurally comprises a first container 110, a mixing tank 120, a first tube 130 and a first flow regulating valve 140.
[0042] The first container 110 is configured to accommodate a first reactant (i.e., a fluorescent substance). Depending on the desired purpose, the fluorescent substance may be a cyanine dye or a fluorescent nanoparticle. In some preferred embodiments, the fluorescent substance is a cyanine dye or a derivative thereof, for example, cyanine dye 3 (Cy3), Cy5, Cy7, indocyanine green (ICG), IR-783, IRDye800, IR830, IR-E1050 or other analogs. Preferably, the cyanine dye is ICG. Alternatively, the fluorescent substance is a fluorescent nanoparticle, for example, a fluorescent gold nanocluster or a silver sulfide quantum dot.
[0043] The mixing tank 120 is configured to receive a second reactant (ie, serum albumin). According to certain embodiments of the present disclosure, the serum albumin may be derived from cows, humans, monkeys, mice, or rats. Preferably, the serum albumin is HSA or BSA.
[0044] Additionally or alternatively, the device 100 further comprises first and second pressure regulating valves, which are respectively coupled to the first container and the mixing tank (110, 120) for controlling the pressures in the first container and the mixing tank.
[0045] According to other embodiments of the present disclosure, the fluorescent substance in the first container 110 is sent to the mixing tank 120 through the first tube 130 and mixed with the serum albumin in the mixing tank 120. To this end, a first flow regulating valve 140 is operably coupled to the first tube 130 to control the flow rate of the fluorescent substance flowing out of the first container 110. Preferably, the first container 110 is vertically arranged above the mixing tank 120, so that the fluorescent substance in the first container 110 flows through the first tube 130 by gravity and enters the mixing tank 120. In addition or alternatively, a stirring member (e.g., a stirring bar, a stirring blade, etc.) is disposed in the mixing tank 120 to mix the contents (e.g., fluorescent substance and serum albumin) in the mixing tank 120.
[0046] The first container 110 and the mixing tank 120 can be any container known in the art for containing liquid, gas or solid reactants. According to a preferred embodiment, the fluorescent substance is present in the first container 110 in liquid form. Depending on the purpose of use, the first container 110 and the mixing tank 120 can be made of translucent or opaque materials. In certain embodiments of the present disclosure, the first container 110 is made of opaque material to protect the fluorescent substance from being irradiated with light. Exemplary materials suitable for manufacturing the first container 110 and the mixing tank 120 include, but are not limited to, glass, polymer materials (e.g., polyethylene, polyvinyl chloride, polypropylene, polystyrene and acrylonitrile butadiene styrene) or other materials that do not react with the first and second reactants in the first container 110 and the mixing tank 120. The prepared NIR-II developer is a complex of a fluorescent substance and serum albumin, wherein the fluorescent substance is coated in serum albumin.
[0047] Figure 2 FIG. 2 is a schematic diagram of a device 200 according to another embodiment of the present disclosure. Figure 1 The structure of the device 100 is similar to that of the device 200 , and the only difference is that the device 200 further includes a second container 250 , a second tube 260 and a second flow regulating valve 270 .
[0048] In this embodiment, the second container 250 is used to contain serum albumin, wherein the second container 250 is vertically disposed above the mixing tank 220. In this case, serum albumin flows out of the second container 250 by gravity and flows through the second tube 250 into the mixing tank 220. Optionally, the flow rate of serum albumin flowing out of the second container 250 is controlled by a second flow regulating valve 270, wherein the second flow regulating valve 270 is operably coupled to the second tube 260. In addition or alternatively, the device 200 further includes a third pressure regulating valve coupled to the second container 250 to control the pressure in the second container 250.
[0049] Similar to the first container 110 and the mixing tank 120 , the second container 250 may be any container known in the art for containing liquid, gas or solid reactants, and may be made of translucent or opaque material.
[0050] Method for preparing NIR-II developer using the device of the present disclosure
[0051] The second aspect of the present disclosure is about using Figure 1 The device 100 shown may utilize Figure 2 The device 200 is shown in the figure to prepare a method of NIR-II developer. According to a preferred embodiment of the present disclosure, the method comprises the following steps:
[0052] (a) adding serum albumin to a mixing tank;
[0053] (b) allowing the fluorescent substance to flow out of the first container 110, enter the mixing tank 120 through the first tube 130, and mix with the serum albumin in the mixing tank 120;
[0054] (c) adjusting the first flow regulating valve 140 to control the flow rate of the fluorescent material flowing out of the first container 110; and
[0055] (d) mixing the contents in the mixing tank 120 of step (c) at a rotation speed of 120 to 1,200 rpm to prepare the NIR-II developer.
[0056] In step (a), serum albumin is first added to the mixing tank 120. According to certain embodiments, the serum albumin may be derived from cows, humans, monkeys, mice or rats. In certain operative examples, the serum albumin is HSA or BSA.
[0057] In step (b), the fluorescent substance in the first container 110 is dripped into the mixing tank 120 by opening the first flow regulating valve 140 to mix with the serum albumin in the mixing tank 120. According to certain embodiments of the present disclosure, the fluorescent substance can be a cyanine dye or a fluorescent nanoparticle. In certain preferred embodiments, the fluorescent substance is a cyanine dye or a derivative thereof; for example, the cyanine dye includes, but is not limited to, Cy3, Cy5, Cy7, ICG, IR-783, IRDye800, IR830, IR-E1050 or the like. Alternatively, the fluorescent substance is a fluorescent nanoparticle. In certain embodiments, the fluorescent nanoparticle is a fluorescent gold nanocluster or a silver sulfide quantum dot.
[0058] In a preferred case, in order to form a desired structure of the complex, the molar concentration of the serum albumin is higher than the molar concentration of the fluorescent substance during the reaction. Therefore, in step (c), the flow rate of the fluorescent substance flowing from the first container 110 to the mixing tank 120 is controlled by adjusting the first flow regulating valve 140 to ensure that the fluorescent substance and the serum albumin are mixed with each other at a desired molar concentration ratio.
[0059] In step (d), the fluorescent substance and serum albumin in the mixing tank 120 of step (c) are uniformly mixed to form the enhanced NIR-II developer of the present disclosure. According to certain embodiments of the present disclosure, the fluorescent substance and serum albumin are mixed at a speed of 120-1,200 rpm. In an operating embodiment, a rotor is placed in the mixing tank to achieve the purpose of stirring.
[0060] According to some preferred embodiments, the molar concentration ratio of the fluorescent substance to the serum albumin in the NIR-II developer is 1:1 to 1:500. For example, the molar concentration ratio of the fluorescent substance to the serum albumin in the NIR-II developer is 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:11, 1:12, 1:13, 1:14, 1:15, 1:16, 1:17, 1:18, 1:19, 1:20, 1:25, 1:30, 1:35, 1:40, 1:45, 1:50, 1:55, 1:60, 1:65, 1:70, 1:75, 1:80, 1:85 , 1:90, 1:95, 1:100, 1:110, 1:120, 1:130, 1:140, 1:150, 1:160, 1:170, 1:180, 1:190, 1:200, 1:250, 255, 1:256, 1:257, 1:258, 1:259, 1:260, 1:265, 1:270, 1:275, 1:280, 1:285, 1:290, 1:295, 1:300, 1:350, 1:410, 1:450 or 1:500. Preferably, the molar concentration ratio of the fluorescent substance to the serum albumin in the NIR-II developer is 1:1 to 1:256. In one working example, the molar concentration ratio of the fluorescent substance to serum albumin in the NIR-II developer is 1:2.
[0061] The third aspect of the present disclosure is about using Figure 2 The device 200 is used to prepare a method for NIR-II developer. The method includes adjusting the first and second flow regulating valves (240, 270) to control the flow rate of the fluorescent substance and serum albumin flowing out of the first and second containers (210, 250) and into the mixing tank 220, respectively, to prepare the NIR-II developer.
[0062] According to some preferred embodiments, the fluorescent substance flows from the first container 210 into the mixing tank 220 , and the serum albumin flows from the second container 250 into the mixing tank 220 .
[0063] Example
[0064] Example 1 Preparation of NIR-II developer
[0065] In this embodiment, using Figure 1 or Figure 2 The device shown is used to prepare NIR-II developer.
[0066] 1.1 Utilization Figure 1 The device shown is used to prepare NIR-II developer
[0067] The fluorescent substance ICG at a concentration of 322.7 μM and the HSA protein at a concentration of 301.2 μM were added to Figure 1 The first container and the mixing tank of the device were added, wherein ICG was dripped into the mixing tank at a flow rate of about 0.35 to 0.41 ml per minute to mix with the HSA solution. Five NIR-II developers were prepared according to the formula in Table 1, and were named IH-1, IH-2, IH-3, IH-4 and IH-5.
[0068] Table 1 Formulas of five NIR-II developers
[0069]
[0070] 1.2 Utilization Figure 2 The device shown is used to prepare NIR-II developer
[0071] The fluorescent substance ICG at a concentration of 322.7 μM and the HSA protein at a concentration of 301.2 μM were added to Figure 2 The ICG and HSA solutions were dripped into the mixing tank. Five NIR-II developers were prepared according to the formula in Table 2, and were named IA-1, IA-2, IA-3, IA-4 and IA-5.
[0072] Table 2 Formulas of five NIR-II developers
[0073]
[0074] Example 2 Confirmation of the NIR-II Developer of the Disclosure
[0075] The NIR-II developer prepared in Example 1 (i.e., IH-1, IH-2, IH-3, IH-4, IH-5, IA-1, IA-2, IA-3, IA-4, and IA-5) was irradiated with light having an excitation wavelength of 780 nm, and the fluorescence signal emitted by the NIR-II developer was detected using a NIR spectrometer. In this experiment, an ICG solution not mixed with HSA was used as a control group.
[0076] From the results shown in Table 3, it can be seen that the NIR-II fluorescence intensity of the control group (i.e., ICG solution) is 214.9, while the NIR-II fluorescence intensities of IH-1, IH-2, IH-3, IH-4, IH-5, IA-1, IA-2, IA-3, IA-4 and IA-5 are 576.0, 709.5, 657.5, 886.6, 852.5, 751.2, 619.7, 806.3, 766.0 and 857.9, respectively.
[0077] Table 3 NIR-II fluorescence intensity of specific NIR-II developers
[0078] <![CDATA[NIR-II fluorescence intensity * (a.u.) ** > Control Group 214.9 IH-1 576.0 IH-2 709.5 IH-3 657.5 IH-4 886.6 IH-5 852.5 IA-1 751.2 IA-2 619.7 IA-3 806.3 IA-4 766.0 IA-5 857.9
[0079] *Fluorescence intensity: The number of fluorescence counts detected within the wavelength range of 900-2,000 nm
[0080] **au (arbitrary units): arbitrary units
[0081] It should be understood that the foregoing description of the embodiments is given by way of example only, and various modifications may be made by those with ordinary knowledge in the technical field to which the present invention belongs. The above description, examples and experimental results provide a complete description of the structure and use of the exemplary embodiments of the present invention. Although various specific embodiments of the present invention are disclosed in the above embodiments, they are not intended to limit the present invention. Those with ordinary knowledge in the technical field to which the present invention belongs may make various changes and modifications to the present invention without departing from the principles and spirit of the present invention. Therefore, the scope of protection of the present invention shall be based on the definition of the appended claims.
Claims
1. A device for preparing a near-infrared-II (NIR-II) developer from a fluorescent substance and a serum albumin, characterized in that: Include: A first container for containing the fluorescent substance; a mixing tank for receiving the serum albumin; A first tube body connected to the first container and the mixing tank; as well as a first flow regulating valve, which is operably coupled to the first tube body and is used to control the flow rate of the fluorescent substance flowing out of the first container; in: The first container is vertically disposed above the mixing tank, so that the fluorescent substance can flow out of the first container and enter the mixing tank through the first tube to mix with the serum albumin to prepare the NIR-II developer; as well as When irradiated with light having an excitation wavelength of 500-830 nm, the NIR-II developer emits NIR-II fluorescence with a wavelength range of 900-2,000 nm.
2. The device according to claim 1, characterized in that Also includes: a second container for containing the serum albumin; a second tube connected to the second container and the mixing tank; and a second flow regulating valve operably coupled to the second tube body for controlling the flow rate of the serum albumin flowing out of the second container; in: The second container is vertically arranged above the mixing tank, so that the serum albumin can flow out of the second container and enter the mixing tank through the tube body.
3. The device according to claim 1, characterized in that It further comprises a mixing element disposed in the mixing tank.
4. The device according to claim 1, characterized in that The invention further comprises a first pressure regulating valve and a second pressure regulating valve, which are respectively coupled to the first container and the mixing tank to control the pressure in the first container and the mixing tank.
5. The device according to claim 2, characterized in that The invention further comprises a third pressure regulating valve which is coupled to the second container and is used for controlling the pressure in the second container.
6. The device according to claim 1, characterized in that The fluorescent substance is a cyanine dye or a fluorescent nanoparticle.
7. The device according to claim 6, characterized in that The fluorescent substance is the cyanine dye.
8. The device according to claim 7, characterized in that The cyanine dye is indocyanine green (ICG).
9. The device according to claim 8, characterized in that The fluorescent substance is the fluorescent nanoparticle, and the fluorescent nanoparticle is a fluorescent gold nanocluster or a silver sulfide quantum dot.
10. The device according to claim 1, characterized in that The serum albumin is human serum albumin (HSA) or bovine serum albumin (BSA).
11. A method for preparing a near-infrared-II (NIR-II) developer using the apparatus as claimed in claim 1, characterized in that: Include: (a) adding the serum albumin to the mixing tank; (b) allowing the fluorescent substance to flow out of the first container, enter the mixing tank through the first tube, and mix with the serum albumin in the mixing tank; (c) adjusting the first flow regulating valve to control the flow rate of the fluorescent substance flowing out of the first container; and (d) mixing the contents in the mixing tank of step (c) at a speed of 120-1,200 revolutions per minute to prepare the NIR-II developer.
12. The method according to claim 11, characterized in that The molar concentration ratio of the fluorescent substance to the serum albumin in the NIR-II developer is 1:1 to 1:
500.
13. The method according to claim 12, characterized in that The molar concentration ratio of the fluorescent substance to the serum albumin is 1:1 to 1:
256.
14. The method according to claim 13, characterized in that The molar concentration ratio of the fluorescent substance to the serum albumin is 1:
2.
15. The method according to claim 11, characterized in that The fluorescent substance is a cyanine dye, a fluorescent gold nanocluster or a silver sulfide quantum dot, and the serum albumin is human serum albumin or bovine serum albumin.
16. A method for preparing a near-infrared-II (NIR-II) developer using the apparatus as claimed in claim 2, characterized in that: The method comprises adjusting the first and second flow regulating valves to respectively control the flow rates of the fluorescent substance and the serum albumin flowing out of the first and second containers and flowing into the mixing tank to prepare the NIR-II developer.
17. The method according to claim 16, characterized in that The molar concentration ratio of the fluorescent substance to the serum albumin in the NIR-II developer is 1:1 to 1:
500.
18. The method according to claim 17, characterized in that The molar concentration ratio of the fluorescent substance to the serum albumin is 1:1 to 1:
256.
19. The method according to claim 18, characterized in that The molar concentration ratio of the fluorescent substance to the serum albumin is 1:
2.
20. The method of claim 16, wherein: The fluorescent substance is a cyanine dye, a fluorescent gold nanocluster or a silver sulfide quantum dot, and the serum albumin is human serum albumin or bovine serum albumin.
